LillyDirect (Zepbound) vs ShedRx (2026): prices, structure, verdict

On tirzepatide, ShedRx↗ is cheaper: $289 versus $449 a month all-in — a $160 monthly gap, $1,920 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, only ShedRx has a rankable figure: $249 a month all-in; LillyDirect (Zepbound)↗ does not offer semaglutide.

§ Side by side

§ Each record, read aloud

The two records, condensed

LillyDirect (Zepbound): the record, condensed

Start with the load-bearing figure: $449 a month, all-in, is what LillyDirect (Zepbound) charges for tirzepatide at the 10 mg basis. Pricing steps with the dose here: from $299 at entry to $449 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $1,800 a year, which is why every ranking on this site uses the larger number.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $449 is the whole subscription, which makes LillyDirect (Zepbound) unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #0 of 17 in the verified tirzepatide index — $234/month above the floor (NexLife↗, $215) — and sits $0 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $5,388.

Operationally at LillyDirect (Zepbound): shipping included (or same-day retail pickup); commitment 45-day refill cadence to keep pricing; cancellation no subscription; refill-window rules apply; pharmacy named (Eli Lilly direct / retail partners); states: 50 states; evidence source-verified, captured 2026-08-09. The full record with source and archive links: the LillyDirect (Zepbound) page · visit LillyDirect (Zepbound) ↗

ShedRx: the record, condensed

ShedRx’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Note the shape: $199 is the number in the marketing, $289 is the number at maintenance. The $90 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #5 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

ShedRx’s semaglutide program bills $249 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The structure is tiered: the advertised entry point is $175, but the maintenance figure — the one a full year is actually billed at — is $249. That $74 gap between the ad and the anniversary is the single most important line in this record.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $249 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

To place the number: #13 of 20 verified programs, with the floor $116/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $100 a month. A year at this figure: $2,988 monthly-billed.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $289 (ShedRx) against $449 (LillyDirect (Zepbound)). $160 a month sounds survivable; $1,920 a year is a decision.

Translate the $160/month spread into medication: $1,920 a year equals roughly 6.6 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: LillyDirect (Zepbound) $449/mo month-to-month versus ShedRx $289/mo month-to-month. Same winner on both bases — ShedRx leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: LillyDirect (Zepbound) $1,347 monthly; ShedRx $867 monthly — best path favors ShedRx by $480. 6 months: LillyDirect (Zepbound) $2,694 monthly; ShedRx $1,734 monthly — best path favors ShedRx by $960. 12 months: LillyDirect (Zepbound) $5,388 monthly; ShedRx $3,468 monthly — best path favors ShedRx by $1,920. 24 months: LillyDirect (Zepbound) $10,776 monthly; ShedRx $6,936 monthly — best path favors ShedRx by $3,840.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

§ Structure vs structure

Everything besides the price

Coverage: LillyDirect (Zepbound) publishes “50 states”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: LillyDirect (Zepbound) names its network (Eli Lilly direct / retail partners); ShedRx does not, which shifts the burden of verification onto your intake questions.

Exit terms: LillyDirect (Zepbound) — 45-day refill cadence to keep pricing; no subscription; refill-window rules apply. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Evidence: LillyDirect (Zepbound) source-verified (captured 2026-08-09); ShedRx source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

§ If you move

Switching between LillyDirect (Zepbound) and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (LillyDirect (Zepbound): no subscription; refill-window rules apply; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings